SCHEMBL4458994

SCHEMBL4458994

COc1c(C(C)(C)C)cc(-c2cccc(C3CCN(C(=O)OC(C)(C)C)CC3)n2)cc1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 6/20 0.47
HPGD P15428 4/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GPR119 Q8TDV5 3/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
CRHBP P24387 2/20 0.45
CRHR2 Q13324 2/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
PRMT5 O14744 2/20 0.42
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
PTK2 Q05397 1/20 0.42
TRPV3 Q8NET8 1/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4456613 0.85 GPR119 (0.48) HTTALDH1A1KDM4EHPGDNPSR1
SCHEMBL4455108 0.84 GPR119 (0.49) HTTALDH1A1KDM4EHPGDNPSR1
SCHEMBL13807216 0.83 HTT (0.46) HTTALDH1A1KDM4EHPGDNPSR1
SCHEMBL4451814 0.82 STS (0.50) HTTKDM4EGPR119MAPTTHRB
SCHEMBL13807217 0.80 HTT (0.43) HTTALDH1A1KDM4EHPGDNPSR1
SCHEMBL4462826 0.80 GRM1 (0.51)
SCHEMBL13807219 0.80 HTT (0.42) HTTALDH1A1KDM4EHPGDNPSR1
SCHEMBL16434944 0.80 HTT (0.51) HTTALDH1A1KDM4EHPGDNPSR1
SCHEMBL4454107 0.79 IRAK4 (0.39) ALDH1A1KDM4E
SCHEMBL30011578 0.78 KDM4E (0.51) HTTKDM4EGPR119MAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators CXCR3, CXCR1, CXCR5 HTT 4698/4885ALDH1A1 1431/4885KDM4E 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.